Fig. 1From: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort studyStudy design. COPD chronic obstructive pulmonary disease, SITT single-inhaler triple therapy, FF/UMEC/VI fluticasone furoate/umeclidinium/vilanterol, HCRU healthcare resource utilizationBack to article page